← Back to Screener
Spyre Therapeutics, Inc. Common Stock (SYRE)
Price$73.39
Favorite Metrics
Price vs S&P 500 (26W)272.71%
Price vs S&P 500 (4W)67.50%
Market Capitalization$5.73B
All Metrics
Book Value / Share (Quarterly)$9.15
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.16
Price vs S&P 500 (YTD)118.72%
Net Profit Margin (TTM)-22158.54%
EPS (TTM)$-2.55
10-Day Avg Trading Volume1.93M
EPS Excl Extra (TTM)$-2.55
EPS (Annual)$-2.42
ROI (Annual)-21.70%
Net Profit Margin (5Y Avg)-8769.93%
Cash / Share (Quarterly)$9.68
ROA (Last FY)-19.95%
EBITD / Share (TTM)$-2.83
ROE (5Y Avg)-86.62%
Operating Margin (TTM)-17559.35%
Cash Flow / Share (Annual)$-2.16
P/B Ratio8.02x
P/B Ratio (Quarterly)3.55x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-6.19x
ROA (TTM)-26.79%
EPS Incl Extra (Annual)$-2.42
Current Ratio (Annual)13.25x
Quick Ratio (Quarterly)12.89x
3-Month Avg Trading Volume0.89M
52-Week Price Return487.84%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)6472.03x
Asset Turnover (Annual)0.00x
52-Week High$75.00
Operating Margin (5Y Avg)-6607.37%
EPS Excl Extra (Annual)$-2.42
26-Week Price Return281.45%
Quick Ratio (Annual)12.89x
13-Week Price Return120.17%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.25x
Enterprise Value$5,648.496
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-38241.08%
Cash / Share (Annual)$9.68
3-Month Return Std Dev74.92%
Net Income / Employee (TTM)$-1
ROE (Last FY)-21.70%
Net Interest Coverage (Annual)-2.14x
EPS Basic Excl Extra (Annual)$-2.42
Receivables Turnover (TTM)2.51x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.55
Receivables Turnover (Annual)2.51x
ROI (TTM)-31.14%
P/S Ratio (TTM)4661.97x
Pretax Margin (5Y Avg)-8771.48%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)452.75%
Year-to-Date Return122.86%
5-Day Price Return15.39%
EPS Normalized (Annual)$-2.42
ROA (5Y Avg)-66.20%
Net Profit Margin (Annual)-38238.15%
Month-to-Date Return44.75%
EBITD / Share (Annual)$-2.81
Operating Margin (Annual)-27347.97%
ROI (5Y Avg)-86.54%
EPS Basic Excl Extra (TTM)$-2.55
P/B Ratio (Annual)3.55x
Pretax Margin (TTM)-22174.80%
Book Value / Share (Annual)$9.15
Price vs S&P 500 (13W)117.31%
Beta3.06x
Revenue / Share (TTM)$0.00
ROE (TTM)-31.14%
52-Week Low$12.04
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.45
4.48
4.48
4.48
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SYRESpyre Therapeutics, Inc. Common Stock | 4661.97x | — | — | — | $73.39 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases. The company's pipeline features extended half-life antibodies targeting α4β7, TL1A, and IL-23, evaluated as monotherapies and pair-wise combinations to improve treatment outcomes and reduce dosing frequency.